WO2023148894A1 - 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 - Google Patents

歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 Download PDF

Info

Publication number
WO2023148894A1
WO2023148894A1 PCT/JP2022/004300 JP2022004300W WO2023148894A1 WO 2023148894 A1 WO2023148894 A1 WO 2023148894A1 JP 2022004300 W JP2022004300 W JP 2022004300W WO 2023148894 A1 WO2023148894 A1 WO 2023148894A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
usag
seq
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/004300
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
克 ▲高▼橋
学 菅井
義人 時田
淳一 ▲高▼木
恵美子 三原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aichi Prefecture
University of Fukui NUC
Kyoto University NUC
University of Osaka NUC
Original Assignee
Osaka University NUC
Aichi Prefecture
University of Fukui NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Aichi Prefecture, University of Fukui NUC, Kyoto University NUC filed Critical Osaka University NUC
Priority to KR1020247029062A priority Critical patent/KR20240141309A/ko
Priority to PCT/JP2022/004300 priority patent/WO2023148894A1/ja
Priority to CN202280092171.4A priority patent/CN118742563A/zh
Priority to US18/835,365 priority patent/US20250136674A1/en
Priority to EP22924804.2A priority patent/EP4474394A4/en
Priority to JP2023578282A priority patent/JPWO2023148894A1/ja
Publication of WO2023148894A1 publication Critical patent/WO2023148894A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to neutralizing antibodies targeting USAG-1 for the treatment of odontia or tooth regeneration.
  • Non-Patent Document 1 Various cells such as stem cells (Non-Patent Document 1) are used as cell sources.
  • Non-Patent Document 2 a cell manipulation technique
  • an object of the present invention is to provide a technique related to a treatment method for edentulousness that utilizes differentiation induction inherent in dental organs, rather than utilizing surgical tissue transplantation.
  • the present inventors succeeded in developing a neutralizing antibody targeting USAG-1. Furthermore, it was found that the administration of the antibody can regenerate missing teeth in congenital anodontia model mice, and can form supernumerary teeth in congenital anodontia model mice or wild-type mice. completed.
  • the present invention [1] An antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, having an amino acid sequence represented by SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and at least 90% of the sequence three heavy chain complementarity determining regions comprising identical amino acid sequences and/or amino acids having at least 90% sequence identity with the amino acid sequences set forth in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively an antibody or antigen-binding fragment thereof comprising three light chain complementarity determining region containing sequences; [2] The antibody or antigen fragment thereof of [1], which specifically binds to USAG-1 and neutralizes the BMP signaling inhibitory activity of USAG-1; [3] The antibody or antigen fragment thereof according to [1] or [2], which specifically binds to USAG-1 and neutralizes the WNT signaling inhibitory activity of USAG-1; [4] A heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity
  • the treatment with the antibody preparation of the present invention can be clinically developed as a regenerative medicine for teeth using conventional dental and oral surgical approaches such as tooth extraction, orthodontics, and tooth transplantation.
  • USAG-1 KO mice established utilizing CRISPER-CAS9 are shown.
  • the results of binding experiments of mouse anti-USAG-1 antibodies to mouse/human USAG-1 proteins are shown.
  • the sequences of the antibody heavy and light chain variable regions are shown.
  • Fig. 2 shows the neutralizing activity of the antibody of the present invention against the WNT signal-suppressing activity and the BMP signal-suppressing activity of mouse USAG-1.
  • FIG. 3 shows the results of a pull-down assay showing the interaction between the mouse anti-USAG-1 antibody/mouse USAG-1 protein complex and the LRP6-E1E2 domain.
  • USAG-1 (Uterine Sensitization Associated Gene-1), also called Sostdc-1, Ectodin, or Wise, is a bone morphogenetic protein (BMP) antagonist and Wnt antagonist.
  • USAG-1-deficient mouse models are known to exhibit increased BMP signaling, leading to supernumerary tooth formation.
  • the inventors crossed Runx2-deficient mice, which are congenital edentulous model mice, and USAG-1 gene-deficient mice, which are supernumerary teeth (teeth that exist more than the number of normal teeth) model mice, to generate double knockout mice. When it was produced and analyzed, it was found that the formation of teeth was restored. Therefore, it was suggested that inhibition of USAG-1 could treat an edentia.
  • an antibody was prepared using a human USAG-1 recombinant protein whose activity was confirmed as an antigen, and an antibody that specifically binds to USAG-1 was obtained. These antibodies were confirmed to increase BMP signaling and/or Wnt signaling.
  • one aspect of the present invention provides antibodies and antigen-binding fragments thereof that specifically bind to and neutralize USAG-1, ie, anti-USAG-1 neutralizing antibodies and antigen-binding fragments thereof.
  • USAG-1 means mammalian USAG-1. Examples of mammals include, but are not limited to, humans, dogs, cats, horses, mice, ferrets, Suncus, pigs, and monkeys, preferably humans.
  • neutralization refers to inhibiting the function of USAG-1.
  • USAG-1 functions include, for example, BMP signaling inhibitory activity (also referred to as “BMP antagonist activity”) and Wnt signaling inhibitory activity (also referred to as “Wnt antagonist activity”).
  • BMP antagonist activity also referred to as "BMP antagonist activity”
  • Wnt signaling inhibitory activity also referred to as "Wnt antagonist activity”
  • Antibodies or antigen-binding fragments thereof of the present application inhibit the BMP signaling inhibitory activity and/or the Wnt signaling inhibitory activity of USAG-1. Accordingly, the antibodies or antigen-binding fragments thereof of the present application neutralize either or both of the BMP signaling inhibitory activity of USAG-1 and the Wnt signaling inhibitory activity of USAG-1.
  • an antibody or antigenic fragment thereof that specifically binds to USAG-1 and neutralizes the BMP signaling inhibitory activity of USAG-1 but does not neutralize the Wnt signaling inhibitory activity of USAG-1 is also an antibody or antigenic fragment thereof of the present application. Included in the antigen-binding fragment. As used herein, "inhibition" includes suppression and reduction.
  • the neutralizing activity of antibodies or antigen-binding fragments thereof may be determined by conventional methods.
  • Activity to neutralize the BMP antagonist activity of USAG-1 (also referred to as “BMP antagonist neutralizing activity”) can be measured in vitro by, for example, an ALP (alkaline phosphatase) assay or a reporter assay.
  • ALP alkaline phosphatase
  • osteoprogenitor cells are cultured in the presence of BMP with the addition of USAG-1 protein and antibody or antigen-binding fragment thereof, and ALP produced when differentiation into osteoblasts is induced is measured. do by doing
  • the activity of USAG-1 to neutralize Wnt antagonist activity (also referred to as "Wnt antagonist neutralizing activity”) can be measured in vitro by, for example, a reporter assay.
  • a vector in which a promoter region that responds to BMP or Wnt is linked to a reporter gene such as luciferase is introduced into cells, and the cells are treated with BMP or Wnt in the presence of USAG-1 protein and antibody or its antigen binding. This is done by adding the fragment, culturing, and measuring the expressed luciferase activity.
  • the BMP antagonist activity neutralized by the anti-USAG-1 antibodies and antigen-binding fragments thereof of the present application can be antagonist activity against any BMP family.
  • anti-USAG-1 antibodies and antigen-binding fragments thereof of the present application can neutralize antagonist activity against, but are not limited to, BMP2, BMP4, BMP6, BMP7, and the like.
  • the Wnt antagonist activity neutralized by the anti-USAG-1 antibodies and antigen-binding fragments thereof of the present application may be antagonist activity against any Wnt family.
  • anti-USAG-1 antibodies and antigen-binding fragments thereof of the present application can neutralize antagonist activity against, but are not limited to, Wnt-1, Wnt-3, and the like.
  • the sequence of one of the obtained antibodies was determined and analyzed, and the variable region and complementarity determining region of the antibody were also determined. That is, the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 1 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 2, the heavy chains being SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 6.
  • a heavy chain variable region comprising The antibody has in particular Wnt antagonist neutralizing activity.
  • the above antibodies and variants thereof are provided as the antibodies of the present application or antigen-binding fragments thereof.
  • An example of the above antibody or variant thereof is an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, wherein the amino acids shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively 3 comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence one heavy chain complementarity determining region or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% with the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively , 95%, 96%, 97%, 98%, or 99% sequence identity.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, wherein three heavy chains comprising the amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof are provided that comprise a complementarity determining region or three light chain complementarity determining regions comprising the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, having at least 80% of the amino acid sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, Three heavy chain complementarity determinations consisting of amino acid sequences with 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity regions or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% of the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10 respectively , 97%, 98%, or 99% sequence identity.
  • antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1, comprising three amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof are provided comprising a heavy chain complementarity determining region or three light chain complementarity determining regions consisting of the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively. .
  • antibodies or variants thereof are antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1 and are set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof having one or more amino acid residue substitutions, deletions, insertions or additions in one or more are provided.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, comprising three heavy chains consisting of the amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively Complementarity determining regions or three light chain complementarity determining regions consisting of the amino acid sequences shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively, and one or more of the above amino acid sequences have 1 to several Antibodies or antigen-binding fragments thereof having amino acid residue substitutions, deletions, insertions or additions are provided.
  • antibodies or variants thereof are antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1, having an amino acid sequence as shown in SEQ ID NO: 3, at least 80%, 85%, A heavy chain variable region comprising an amino acid sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity or SEQ ID NO:4 amino acids having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in An antibody or antigen-binding fragment thereof is provided that includes a light chain variable region containing sequence.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, the heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:3, or the amino acid shown in SEQ ID NO:4
  • An antibody or antigen-binding fragment thereof is provided that includes a light chain variable region containing sequence.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1 and has an amino acid sequence represented by SEQ ID NO: 3 and at least 80%, 85%, 90%, 91%, 92% %, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity, or at least the amino acid sequence shown in SEQ ID NO:4 a light chain variable region consisting of an amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity
  • Antibodies or antigen-binding fragments thereof comprising: Still more preferably, an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 3, or the heavy chain variable region shown in SEQ ID NO: 4
  • Antibodies or antigen-binding fragments thereof are provided that comprise a light chain variable region consisting of an amino
  • antibodies or variants thereof include an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, the heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 3, or , an antibody or an antigen thereof, comprising a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 4, wherein one to several amino acid residues are substituted, deleted, inserted or added in one or more of the above amino acid sequences Binding fragments are provided.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 3, or the amino acid shown in SEQ ID NO: 4
  • Antibodies or antigen-binding fragments thereof are provided, comprising a light chain variable region consisting of a sequence in which one to several amino acid residues have been substituted, deleted, inserted or added in one or more of the above amino acid sequences.
  • antibodies or variants thereof are antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1 and are set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively. Include amino acid sequences having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence three heavy chain complementarity determining regions and at least 80%, 85%, 90%, 91%, 92%, 93%, 94% with the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively , 95%, 96%, 97%, 98%, or 99% sequence identity.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, wherein three heavy chains comprising the amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof are provided that comprise a complementarity determining region and three light chain complementarity determining regions comprising the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, having at least 80% of the amino acid sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, Three heavy chain complementarity determinations consisting of amino acid sequences with 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity regions, and at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, with the amino acid sequences set forth in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively; Antibodies or antigen-binding fragments thereof are provided that comprise three light chain complementarity determining regions consisting of amino acid sequences with 97%, 98% or 99% sequence identity.
  • antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1, comprising three amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof are provided comprising a heavy chain complementarity determining region and three light chain complementarity determining regions consisting of the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively.
  • antibodies or variants thereof are antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1 and are set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • Antibodies or antigen-binding fragments thereof having one to several amino acid residues substituted, deleted, inserted or added as described above are provided.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, comprising three heavy chains consisting of the amino acid sequences set forth in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively Complementarity determining region and three light chain complementarity determining regions consisting of the amino acid sequences shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively, one to several amino acids in one or more of the above amino acid sequences
  • Antibodies or antigen-binding fragments thereof with substituted, deleted, inserted or added residues are provided.
  • antibodies or variants thereof are antibodies or antigen-binding fragments thereof that specifically bind to and neutralize USAG-1, having an amino acid sequence as shown in SEQ ID NO: 3, at least 80%, 85%, a heavy chain variable region comprising an amino acid sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity and SEQ ID NO:4 Amino acid sequences having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the indicated amino acid sequence
  • Antibodies or antigen-binding fragments thereof are provided that comprise a light chain variable region comprising:
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1 the heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:3 and the amino acid sequence shown in SEQ ID NO:4 Antibodies or antigen-binding fragments thereof
  • antibodies or variants thereof include an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, the heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 3, and An antibody or antigen-binding thereof, comprising a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 4, wherein one to several amino acid residues are substituted, deleted, inserted or added in one or more of the above amino acid sequences Fragments are provided.
  • an antibody or antigen-binding fragment thereof that specifically binds to and neutralizes USAG-1, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO:3 and the amino acid sequence shown in SEQ ID NO:4 and having one to several amino acid residue substitutions, deletions, insertions or additions in one or more of the above amino acid sequences, or antigen-binding fragments thereof, are provided.
  • “several” refers to about 2 to 10, preferably about 2 to 7, for example, 3, 4, 5, or 6, depending on the length of the amino acid sequence.
  • substitution may be conservative substitution or non-conservative substitution, preferably conservative substitution.
  • Conservative substitutions are known to those of skill in the art and refer to substitutions that do not alter the biological activity of the resulting molecule. Examples of conservative amino acid substitutions are alanine for glycine or serine, arginine for lysine or histidine, asparagine for glutamine or histidine, aspartic acid for glutamic acid or asparagine, cysteine for serine or alanine.
  • glutamine to asparagine glutamic acid to aspartic acid or glutamine, glycine to alanine, histidine to asparagine or glutamine, isoleucine to leucine or valine, leucine to isoleucine or lysine to arginine or histidine; methionine to leucine, isoleucine or tyrosine; phenylalanine to tyrosine, methionine or leucine; proline to alanine; serine to threonine; Substitutions include threonine to serine, tryptophan to tyrosine or phenylalanine, tyrosine to tryptophan or phenylalanine, and valine to isoleucine or leucine.
  • sequence identity may be determined by optimally aligning two sequences and following a conventional method. For example, it may be determined using algorithms known in the art such as BLAST and FASTA.
  • the antibodies or antigen-binding fragments thereof of the present application may have amino acid residue substitutions, deletions, insertions or additions within the range of sequence identity described above.
  • the antibody or antigen-binding fragment thereof of the present application has the same epitope on USAG-1 to which the above-described antibody, or variant or antigen-binding fragment thereof binds.
  • Antibodies or antigen-binding fragments thereof that bind in whole or in part are provided.
  • the antibodies compete for binding to USAG-1 or for binding to all or part of an epitope on USAG-1 with the above-described antibodies or variants or antigen-binding fragments thereof.
  • antibodies or antigen-binding fragments thereof are provided.
  • Compet means that an antibody or antigen-binding fragment thereof competes against a reference antibody (e.g., the above antibody or variant or antigen-binding fragment thereof) in a binding assay using a USAG-1 protein or polypeptide. ).
  • a test antibody "competes" with a reference antibody if the test antibody or antigen-binding fragment thereof reduces binding of the reference antibody to a USAG-1 protein or polypeptide in a binding assay.
  • An antibody that competes with a reference antibody reduces binding of the reference antibody to an antigenic protein or polypeptide by at least about 40%, preferably at least about 50%, more preferably at least about 60%, even more preferably at least about 80%. , more preferably by at least 90%.
  • epitope binning is a technique for classifying two or more antibodies based on their epitopes using the SPR method or the BLI method.
  • an antigen protein target
  • the reference antibody and target are allowed to bind, and then a biosensor holding a complex of the reference antibody and target is prepared.
  • a test antibody is reacted and the binding of the test antibody to the biosensor (ie, to a target captured by a reference antibody immobilized on the biosensor) and dissociation is analyzed.
  • test antibody shares the same epitope as the reference antibody, the test antibody cannot bind to the biosensor because the epitope on the target is already occupied by binding the reference antibody. Conversely, if a test antibody recognizes a different epitope than the reference antibody, it can bind to the biosensor. Furthermore, if the test antibody recognizes a region that is conformationally close to the epitope of the reference antibody, the binding of the reference antibody to the target interferes with the binding of the test antibody to the epitope. Unable to bind to sensor. Thus, epitope binning can be used to determine whether two or more antibody clones compete for binding to the target protein.
  • Antibodies or antigen-binding fragments thereof of the present application have a KD of, for example, 1 ⁇ M or less, preferably 100 nM or less, more preferably 50 nM or less, even more preferably 30 nM or less, more preferably 10 nM or less, even more preferably 8 nM or less, even more preferably 5 nM or less. Values bind to all or part of USAG-1 or an epitope on USAG-1.
  • antibodies are preferably isolated antibodies.
  • antibodies may be either polyclonal antibodies or monoclonal antibodies.
  • antibodies may be human antibodies, humanized antibodies, chimeric antibodies, or multispecific antibodies (eg, bispecific antibodies).
  • Humanized antibodies are those in which residues from the complementarity determining regions (CDRs) of the recipient are replaced by residues from the CDRs of a species other than human (the donor antibody) that have the desired specificity, affinity and binding ability.
  • human immunoglobulin receptor antibody
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are found in the recipient or donor antibody.
  • a humanized antibody has at least one typical antibody in which all or substantially all of the CDRs have been replaced with those of a non-human immunoglobulin and all or substantially all of the FR regions are of human immunoglobulin sequences. Typically, it contains two variable regions.
  • Chimeric antibodies include antibodies produced by genetic engineering techniques in which the variable regions from a donor antibody are linked to the constant regions of the recipient antibody. The above antibodies can be produced by methods known in the art.
  • antigen-binding fragments include, but are not limited to, F(ab′) 2 , Fab′, Fab, Fv, rIgG, Fd, linear antibodies, ScFv, Fv-clasp, minibodies, They include diabodies, triabodies, tetrabodies, single domain antibodies (nanobodies), multispecific antibodies formed from antibody fragments, and the like. Production of the above antibody fragments can be performed by methods known in the art.
  • An isolated nucleic acid encoding the antibody of the present application or an antigen-binding fragment thereof is also included in the present invention.
  • the antibody or antigen-binding fragment thereof of the present application specifically binds to USAG-1, inhibits the function of USAG-1, and induces tooth formation.
  • another aspect of the present invention provides a pharmaceutical composition for dental regeneration treatment comprising an antibody or antigen-binding fragment thereof of the present application.
  • tooth regeneration includes, for example, regeneration of missing teeth (restoration of missing teeth) and formation of new teeth such as third teeth.
  • the pharmaceutical composition of the present application may contain additives such as pharmaceutically acceptable carriers, stabilizers and excipients in addition to the antibody or antigen-binding fragment thereof of the present application.
  • Pharmaceutically acceptable carriers include, but are not limited to, saline, buffers, glycols, glycerol, gelatin, gelatin hydrogel, polylactic acid, collagen sponge, agarose, polyvinyl alcohol, alginic acid, fibrin gel, Ethylene-vinyl acetate copolymers, lactic acid-glycolic acid copolymers, and the like can be mentioned.
  • additives include, but are not limited to, carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, and the like. Those skilled in the art can appropriately select the above carriers and additives based on the dosage form, administration route, etc. of the pharmaceutical composition.
  • the pharmaceutical composition of the present application can be produced by formulating the above antibody or antigen-binding fragment thereof and optionally the above additives by a conventional method.
  • compositions of the present application include, for example, tablets, powders, capsules, granules, syrups, sustained-release tablets, sustained-release capsules, enteric agents, inserts, injections, injections, and the like. An injection is preferred.
  • the pharmaceutical compositions of the present application are administered by systemic or local administration.
  • the route of administration may be appropriately selected by those skilled in the art, and examples thereof include, but are not limited to, oral, nasal, subcutaneous, intravenous, intramuscular, and intraosseous administration.
  • the pharmaceutical compositions of the present application may be administered topically, for example to the site of tooth formation.
  • tooth regeneration treatment includes treatment of congenital anedentia and treatment of acquired tooth loss.
  • congenital anodontia that can be treated with the pharmaceutical composition of the present application, and it may be congenital anodontia caused by any causative gene.
  • congenital anodontia treatable with the pharmaceutical compositions of the present application include, but are not limited to, congenital anodontia caused by RUNX2, MSX1, EDA, WNT10A, PAX9, or AXIN2. and preferably congenital anodontia in which RUNX2, MSX1, EDA, or WNT10A is the causative gene.
  • Antibodies of the present application also induced formation of supernumerary teeth in wild-type mice. Therefore, the pharmaceutical composition of the present application can induce tooth formation in both normal individuals without deletion of the causative gene for odontia and individuals with acquired tooth loss.
  • the subject of administration of the pharmaceutical composition of the present application includes mammals such as humans, dogs, cats, horses, mice, ferrets, Suncus, pigs, and monkeys, preferably humans.
  • the dosage of the pharmaceutical composition of the present application is not particularly limited. Based on the content of the antibody of the present application or the antigen-binding fragment thereof in the pharmaceutical composition, the weight of the subject to be administered, etc., the desired dose of the antibody of the present application or the antigen-binding fragment thereof is appropriately determined by those skilled in the art. can do.
  • the antibody or antigen-binding fragment thereof of the present application increases the BMP signal by at least 30%, preferably by at least 60%, and/or the Wnt signal by at least 30%, preferably by at least 60% compared to when not administered. It is administered in an amount that exhibits % increasing neutralizing activity.
  • the neutralizing activity may be determined based on the activity measured in vitro by, for example, ALP assay or reporter assay.
  • a further aspect of the present invention provides a method for tooth regeneration treatment comprising administering the antibody of the present application or an antigen-binding fragment thereof to a subject in need of treatment.
  • the pharmaceutical compositions described above can be used as the antibodies or antigen-binding fragments thereof of the present application.
  • a subject in need of treatment is a subject with missing teeth, such as the mammals described above.
  • the route of administration and dosage of the antibody or antigen-binding fragment thereof of the present application, as well as the tooth regeneration treatment, are as described above for the pharmaceutical composition of the present application.
  • the obtained antibody clones were subjected to primary screening by ELISA using the immunized antigen (rat USAG-1 protein derived from the baculovirus expression system) and the human USAG-1 protein derived from the E. coli expression system. was accepted. A cutoff value of 1.0 was set and 111 clones were selected. Sandwich ELISA was performed using the expanded culture and immunized antigen, and when the absorbance cutoff value was set to 0.5 or more (His tag) and 1.4 or more (Myc tag), about half of the positive wells were found. Admitted. Antibody subclasses were determined to be IgG1, 2a, 2b, and G3.
  • each antibody obtained was evaluated by adding 300 ng/ml of BMP7 (manufactured by R&D Systems) to C2C12 cells in the same manner as the antigen protein.
  • BMP7 manufactured by R&D Systems
  • Various antibodies were added to an experimental system in which 300 ng/ml of 1 protein (MyBiosource) was added to inhibit ALP activity, and neutralization of inhibition of ALP activity was confirmed. Mild neutralizing activity (*: 60-100% neutralizing activity), moderate neutralizing activity (**: 100-140% neutralizing activity), high neutralizing activity It was classified into those for which activity was recognized (***: 140% or more neutralizing activity).
  • BMP reporter assay a commercially available cell line BMP Responsive Reporter Osteoblast Cell Line (Briter cell) (manufactured by Kerafast) incorporating BRE-Luc was used.
  • BMP7 was added to suppress the expressed luciferase activity by adding 300 ng/ml of mammalian cell expression system-derived rat USAG-1 protein, and neutralization of luciferase activity suppression was confirmed. . It was classified into those with mild neutralizing activity (*: 40-60% neutralizing activity) and those with moderate neutralizing activity (**: 60% or more neutralizing activity).
  • the WNT reporter assay includes a TOP-Flash reporter gene with a DNA sequence that binds to the transcription factor TCF that is activated downstream of the WNT signal, the WNT1 gene, and the HSV-thymidine kinase promoter to obtain an internal standard.
  • a system was used in which mouse USAG-1 protein derived from a mammalian cell expression system was added to HEK293 cells into which an expression plasmid for expressing a reporter gene was introduced, at a concentration that inhibits 50% of the maximum inhibitory effect of Wnt signals (EC50), and cultured. .
  • the amount of USAG-1 protein to be added was determined in advance.
  • the percentage of neutralizing activity was calculated based on the activity (100%) under USAG-1 protein-free conditions.
  • the neutralizing activity based on the luminescence value was calculated with the activity when no antibody was added as 1.
  • a mouse anti-USAG-1 neutralizing antibody (B48C) was secured.
  • mouse anti-USAG-1 neutralizing antibody B48C can recognize the human USAG-1 protein
  • three antibodies B14, B103 , B108
  • binding assays using mouse/human N-terminal PA-tagged USAG-1 proteins were performed.
  • Each mouse anti-USAG-1 neutralizing antibody 250 ⁇ l Protein A/G IgG binding buffer (Pierce TM ) + 5 ⁇ g in 250 ⁇ l PBS
  • the sequence of antibody B48C was determined.
  • the full-length heavy chain sequence containing the signal sequence of the antibody is shown in SEQ ID NO:1, and the full-length light chain sequence containing the signal sequence is shown in SEQ ID NO:2.
  • the variable region of the antibody is shown in FIG.
  • each of the nine antibodies is immobilized on a biosensor as a capture antibody, and a target containing purified recombinant murine USAG-1 full-length is added and allowed to bind, followed by reaction with a test antibody to generate a binding signal. Cycles of detection were performed consecutively for nine test antibodies, including the same antibody used for capture. An antibody whose recognition site does not compete with the capture antibody immobilized on the biosensor can bind to the captured USAG-1 protein, resulting in an increase in signal. None or reduced. Based on the signal data obtained, 9 antibodies were grouped with respect to their epitopes. Table 1 shows the results.
  • the affinity (KD value) of the antibody obtained in Example 1 was determined using the BLI method using Octet (registered trademark) Red (manufactured by Pall ForteBio). Specifically, after immobilizing the antibody on the biosensor, purified recombinant mouse USAG-1 protein was added at three different concentrations (10 nM, 30 nM, 100 nM) to obtain respective binding and dissociation curves. , were calculated by global fitting using an analysis program attached to the Octet apparatus. The result showed a KD value of 3.26 nM.
  • Antibody in vitro test 2 Antibody B48C sequenced in Example 1 was measured for BMP and Wnt signaling suppression neutralizing activity. Experiments were performed with mouse USAG-1 recombinant protein. After confirming the transient expression of mouse USAG-1 (WISE) recombinant protein with a PA tag added to the N-terminus in Expi293F cells, a stable expression strain was established. Affinity purification was performed using the PA tag system to yield 0.2 mg of PA-mUSAG-1 (WISE) from 150 mL of culture supernatant.
  • WISE mouse USAG-1
  • Purified PA-mUSAG-1 (WISE) protein showed a molecular weight of approximately 28 kDa, close to the theoretical value (24 kDa), under reducing (R) and non-reducing (NR) electrophoresis.
  • Mammalian Expi293F cell expression system-derived mouse N-terminal PA-tagged USAG-1 (WISE) protein dose-dependently suppresses WNT signal in WNT reporter assay, and dose-dependently suppresses BMP signal in BMP ALP assay. showed activity. Using the mouse USAG-1 protein for which this activity was confirmed, the neutralizing activity of the above antibody was confirmed.
  • the WNT reporter assay cells transfected with a vector in which a promoter is linked to the luciferase gene and a Wnt1 expression vector (1 ⁇ g) were treated with 1 ⁇ g of mouse USAG-1 recombinant protein, antibody with 1, 3, 6, 10, or It was added to 30 ⁇ g/ml and cultured, and the luciferase activity was measured.
  • C2C12 cells were treated with 30 ng/ml of murine USAG-1 recombinant protein in the presence of 30 ng/ml of BMP7, 0.1-fold (3 ng/ml), 10-fold (300 ng/ml) or 100-fold volume of antibody.
  • LRP6 low-density lipoprotein receptor-related protein 5/6 receptors, which are Frizzled-coupled receptors, and transmit signals into cells.
  • LRP6 has four extracellular domains (E1 to E4), of which E1E2 is known to be involved in USAG-1 binding. That is, USAG-1 binds to the E1E2 region of LRP6 and suppresses Wnt signaling. Therefore, neutralizing antibodies (E12, E16, E37, E48, E57, B14, B103, E48, E57, B14, B103, B108) to determine whether it inhibits the binding of USAG-1 to LRP6-E1E2.
  • Each mouse anti-USAG-1 neutralizing antibody (5 ⁇ g in 1 ml PBS) was captured on Protein A Sepharose (30 ⁇ l) (room temperature, 1.5 hours).
  • a culture supernatant (1 mL) in which mouse USAG-1 recombinant protein with a PA tag added to the N-terminus was transiently expressed in Expi293F cells was added thereto and incubated (room temperature, 2 hours).
  • NZ-1-immunoprecipitated WISE+E1E2 By NZ1
  • LRP6-E1E2-only expression levels precipitated with His-tag-adsorbing Ni-NTA resin E1E2 By NiNTA are shown in the right panels.
  • Example 1 The antibody obtained in Example 1 is intraperitoneally administered once to a mother mouse pregnant with a congenital reminda model mouse EDA homodeficient, a congenital reminda model mouse EDA heterodeficient, or a wild-type mouse. (16 ⁇ g/g body weight). Presence of supernumerary teeth and fused teeth and restoration of missing teeth were examined in the pups born. Table 2 shows the results. The antibody specifically restored missing teeth in EDA-deficient mice.
  • the term "recovery” refers to the fact that the EDA-deficient mouse that was born has teeth at the site (M3) that is normally deficient in the EDA-deficient mouse (M3 is not deficient).
  • Example 2 The antibody obtained in Example 1 was intraperitoneally administered once to a mother mouse pregnant with a congenital reminda model mouse Wnt10a homozygous, a congenital reminda model mouse Wnt10a heterozygous, or a wild-type mouse. (16 ⁇ g/g body weight). Presence of supernumerary teeth and fused teeth and restoration of missing teeth were examined in the pups born. Table 3 shows the results. The antibody induced the formation of supernumerary and fused teeth in homozygous mice.
  • the antibody or antigen-binding fragment thereof of the present application can be used to treat congenital anodontia and acquired tooth loss.
  • the antibody or antigen-binding fragment thereof of the present application is considered to be effective for 3rd dentition formation, and development of molecular target drugs for tooth regeneration in the pharmaceutical field and formation of 3rd dentition This will lead to the establishment of a treatment method that regenerates teeth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2022/004300 2022-02-03 2022-02-03 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 Ceased WO2023148894A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020247029062A KR20240141309A (ko) 2022-02-03 2022-02-03 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체
PCT/JP2022/004300 WO2023148894A1 (ja) 2022-02-03 2022-02-03 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
CN202280092171.4A CN118742563A (zh) 2022-02-03 2022-02-03 靶向usag-1分子的用于牙齿再生治疗的中和抗体
US18/835,365 US20250136674A1 (en) 2022-02-03 2022-02-03 Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
EP22924804.2A EP4474394A4 (en) 2022-02-03 2022-02-03 Neutralizing antibody targeting a molecule called USAG-1 for treating tooth regeneration
JP2023578282A JPWO2023148894A1 (https=) 2022-02-03 2022-02-03

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2022/004300 WO2023148894A1 (ja) 2022-02-03 2022-02-03 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Publications (1)

Publication Number Publication Date
WO2023148894A1 true WO2023148894A1 (ja) 2023-08-10

Family

ID=87553416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/004300 Ceased WO2023148894A1 (ja) 2022-02-03 2022-02-03 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Country Status (6)

Country Link
US (1) US20250136674A1 (https=)
EP (1) EP4474394A4 (https=)
JP (1) JPWO2023148894A1 (https=)
KR (1) KR20240141309A (https=)
CN (1) CN118742563A (https=)
WO (1) WO2023148894A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021010346A1 (ja) 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043841A1 (en) * 2020-02-21 2024-02-08 Kyoto University Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021010346A1 (ja) 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
JP2021176829A (ja) * 2019-07-12 2021-11-11 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ−１を標的分子とした中和抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MURASHIMA-SUGINAMI A., KISO H., TOKITA Y., MIHARA E., NAMBU Y., UOZUMI R., TABATA Y., BESSHO K., TAKAGI J., SUGAI M., TAKAHASHI K.: "Anti–USAG-1 therapy for tooth regeneration through enhanced BMP signaling", SCIENCE ADVANCES, vol. 7, no. 7, 12 February 2021 (2021-02-12), XP093082516, DOI: 10.1126/sciadv.abf1798 *
NAKAO, NAT METHODS, 2007
OHAZAMA, J DENR RES, 2004
See also references of EP4474394A4

Also Published As

Publication number Publication date
JPWO2023148894A1 (https=) 2023-08-10
KR20240141309A (ko) 2024-09-26
US20250136674A1 (en) 2025-05-01
EP4474394A4 (en) 2026-04-15
CN118742563A (zh) 2024-10-01
EP4474394A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP7227312B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP7044399B2 (ja) タウ免疫療法
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
CN107207588B (zh) 针对tau的抗体和其用途
JP2020537509A (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
JP6900051B2 (ja) Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
US10556947B2 (en) Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor
JP2025004094A (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
TW202342101A (zh) 抗EphA4抗體
FR3075200A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
JPWO2020059847A1 (ja) ヒトｈｍｇｂ１に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
JP2024508709A (ja) 抗ｃｄ１２３結合分子及びその使用法
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
TW202216773A (zh) 識別分選蛋白(sortilin)的抗體
KR20180098570A (ko) 항-ｍｙｌ9 항체
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
CN104487092B (zh) 对于由阻碍整合素α8β1功能引起的纤维化的抑制
WO2023148894A1 (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
WO2018207638A1 (ja) 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
HK40114319A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
US20240254219A1 (en) Novel wnt agonist antibodies and therapeutic uses thereof
HK40073445A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40107636A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40073445B (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
WO2022124247A1 (ja) 前頭側頭葉変性症の予防又は治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22924804

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023578282

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 18835365

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 202280092171.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 202447063666

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20247029062

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022924804

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022924804

Country of ref document: EP

Effective date: 20240903

WWP Wipo information: published in national office

Ref document number: 18835365

Country of ref document: US